Paris, April 24th, 2019 – 7:00 CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, today announced two presentations of interim clinical results with the breakthrough PRIMA bionic vision system in atrophic dry age-related macular degeneration (dry-AMD), at the Association for Research in Vision and Ophthalmology (ARVO) 2019 world congress in Vancouver (Canada) April 28 – May 2. ARVO is the main annual event for research and innovation in ophthalmology. The presentations consist of 2 podium talks, that will include the latest insights into PRIMA’s clinical performance and safety results in dry-AMD.

A Stanford University team will present positive clinical results and safety profile achieved with the PRIMA bionic vision system in humans. The patients implanted with the wireless sub-retinal PRIMA microchip continue to demonstrate improvements during the course of their rehabilitation. This data is being utilized in the design of the multi-center and multi-country European pivotal study for CE mark approval.

The presentations on PRIMA include:

  • Photovoltaic restoration of sight in age-related macular degeneration

D. Palanker
Presentation Abstract Number: 2 – Symposium, April 28 - 8:25 – 8:44 East Ballroom A

  • Restoration of Sight in Geographic Atrophy using a Photovoltaic Subretinal Prosthesis

D. Palanker et al.
Presentation Abstract Number: 970 Paper Session Sun, April 28 - 3:00 – 3:15 East 8 & 15

To view Pixium Vision related abstracts please click here: ARVO2019

Contacts

Pixium Vision

 

Didier Laurens, CFO
investors@pixium-vision.com

+33 1 76 21 47 68
Media Relations
Newcap Media
Annie-Florence Loyer - afloyer@newcap.fr

+33 1 44 71 00 12 / +33 6 88 20 35 59
Léa Jacquin - ljacquin@newcap.fr

+33 1 44 71 94 94
US Investor Relations
ICR
David Clair
david.clair@icrinc.com

+1 646 277 12 66

 


ABOUT PRIMA

PRIMA is a new generation miniaturized and totally wireless sub-retinal implant. The 2x2 millimeters wide and 30 microns thick photovoltaic chip contains 378 electrodes. Implanted under the retina via a minimally invasive surgical procedure, it acts like an array of tiny solar panel powered by pulsed near infrared light projected from a miniature projector integrated into augmented reality glasses, along with a mini-camera. PRIMA is designed to restore sight in patients blinded by retinal dystrophies – a very significant unmet medical need. The target population includes patients with atrophic dry Age-related Macular Degeneration (dry AMD), and also Retinitis Pigmentosa (RP). In addition to a clinical trial with five atrophic dry-AMD patients in France, PRIMA is approved for a similar five-patients study in USA.

ABOUT AGE-RELATED MACULAR DEGENERATION (AMD)

Age-related macular degeneration is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. The global impact is significant with current projected estimates1 for people living with AMD of around 196 million people worldwide and expected rapid growth due to ageing population. Around 1000 new patients are diagnosed everyday just in Europe and USA. There are two forms of advanced AMD: the wet form, where treatment like anti-VEGF injections slows down the disease progression, and the dry form that is most frequent, where there is currently no curative treatment available. More than 5 million patients are afflicted with advanced dry AMD, also referred to as Geographic Atrophy. Patients suffering from this retinal dystrophy gradually lose their central vision (responsible for high visual acuity, e.g. for reading and face recognition) due to loss of photoreceptors.

ABOUT PIXIUM VISION

Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Pixium Vision is in clinical stage with PRIMA, its sub-retinal miniature photovoltaic wireless implant system, designed for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information, please visit:   www.pixium-vision.com;
 And follow us on:  @PixiumVision;   www.facebook.com/pixiumvision

               www.linkedin.com/company/pixium-vision

Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.   Pixium Vision is included in the Euronext CAC All Shares index   Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

 


Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com




1 Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C. Y., & Wong, T. Y. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health, 2(2), e106-e116 (https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70145-1/fulltext)


Attachment